Logan P. Jones

Array ( [id] => 8732613 [patent_doc_number] => 20130078182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-28 [patent_title] => 'Structural Variants of Antibodies for Improved Therapeutic Characteristics' [patent_app_type] => utility [patent_app_number] => 13/617059 [patent_app_country] => US [patent_app_date] => 2012-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 39651 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13617059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8814146 [patent_doc_number] => 20130115191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/612178 [patent_app_country] => US [patent_app_date] => 2012-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 14289 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13612178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8617296 [patent_doc_number] => 20130022607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-24 [patent_title] => 'MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/600789 [patent_app_country] => US [patent_app_date] => 2012-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 29141 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13600789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8950066 [patent_doc_number] => 20130195846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-01 [patent_title] => 'COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/598421 [patent_app_country] => US [patent_app_date] => 2012-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10475 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13598421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8522213 [patent_doc_number] => 20120321621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-20 [patent_title] => 'INHIBITION OF FcyR-MEDIATED PHAGOCYTOSIS WITH REDUCED IMMUNOGLOBULIN PREPARATIONS' [patent_app_type] => utility [patent_app_number] => 13/595662 [patent_app_country] => US [patent_app_date] => 2012-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 11981 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13595662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8696933 [patent_doc_number] => 20130058943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-07 [patent_title] => 'BOVINE POLYCLONAL ANTIBODY SPECIFIC FOR HUMAN TNF' [patent_app_type] => utility [patent_app_number] => 13/564566 [patent_app_country] => US [patent_app_date] => 2012-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 27191 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13564566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9602619 [patent_doc_number] => 20140199300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-17 [patent_title] => 'COMBINATION THERAPY FOR THE TREATMENT OF CD19+ B-CELL MALIGNANCIES SYMPTOMS COMPRISING AN ANTI-CD1 MAYTANSINOID IMMUNOCONJUGATE AND RITUZIMAB' [patent_app_type] => utility [patent_app_number] => 14/235569 [patent_app_country] => US [patent_app_date] => 2012-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6236 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14235569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8566509 [patent_doc_number] => 20120329080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-27 [patent_title] => 'ANTI-HLA ASSAY AND METHODS' [patent_app_type] => utility [patent_app_number] => 13/553447 [patent_app_country] => US [patent_app_date] => 2012-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 16471 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13553447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9670435 [patent_doc_number] => 20140234298 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'THERAPEUTIC COMBINATIONS OF ANTI-CD20 AND ANTI-GM-CSF ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/130667 [patent_app_country] => US [patent_app_date] => 2012-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 6769 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14130667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13024605 [patent_doc_number] => 10034915 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-31 [patent_title] => Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia [patent_app_type] => utility [patent_app_number] => 13/531114 [patent_app_country] => US [patent_app_date] => 2012-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 22 [patent_no_of_words] => 18332 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13531114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8429659 [patent_doc_number] => 20120251534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-04 [patent_title] => 'COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/524800 [patent_app_country] => US [patent_app_date] => 2012-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12313 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13524800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8441489 [patent_doc_number] => 20120258102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/524896 [patent_app_country] => US [patent_app_date] => 2012-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12316 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13524896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8441484 [patent_doc_number] => 20120258101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/524858 [patent_app_country] => US [patent_app_date] => 2012-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12319 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13524858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8452766 [patent_doc_number] => 20120263713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-18 [patent_title] => 'Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone' [patent_app_type] => utility [patent_app_number] => 13/490351 [patent_app_country] => US [patent_app_date] => 2012-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13082 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13490351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8502085 [patent_doc_number] => 20120301492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-29 [patent_title] => 'COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 13/481674 [patent_app_country] => US [patent_app_date] => 2012-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 34061 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13481674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8335117 [patent_doc_number] => 20120201818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-09 [patent_title] => 'TREATMENT OF MULTIPLE SCLEROSIS' [patent_app_type] => utility [patent_app_number] => 13/450377 [patent_app_country] => US [patent_app_date] => 2012-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16088 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13450377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9569176 [patent_doc_number] => 20140186889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-03 [patent_title] => 'ANTIBODY GENERATION FROM PLASMACYTOMA-PRONE TRANSGENIC ANIMALS' [patent_app_type] => utility [patent_app_number] => 14/111978 [patent_app_country] => US [patent_app_date] => 2012-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5135 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14111978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9369825 [patent_doc_number] => 20140079698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-20 [patent_title] => 'ANTI-TUMOR ANTIBODY-TUMOR SUPPRESSOR FUSION PROTEIN COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/009833 [patent_app_country] => US [patent_app_date] => 2012-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 11376 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14009833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8332816 [patent_doc_number] => 20120199516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-09 [patent_title] => 'METHOD FOR TREATING MULTIPLE SCLEROSIS' [patent_app_type] => utility [patent_app_number] => 13/440916 [patent_app_country] => US [patent_app_date] => 2012-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 24766 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13440916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11218861 [patent_doc_number] => 09447189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-20 [patent_title] => 'CD37-binding molecules and immunoconjugates thereof' [patent_app_type] => utility [patent_app_number] => 13/436528 [patent_app_country] => US [patent_app_date] => 2012-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 36522 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 271 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13436528 [rel_patent_id] =>[rel_patent_doc_number] =>)